Fresenius
Corporate brand
UnclaimedGerman global healthcare group spanning essential medicines, medical technology, hospitals, and an equity investment in Fresenius Medical Care.
Last updated October 14, 2026
AI crawler reads
No AI crawler has read this profile since Oct 28, 2026.
Overview
Fresenius is a German multinational healthcare group headquartered in Bad Homburg vor der Höhe. Its origins lie in the laboratory of the Hirsch Pharmacy in Frankfurt, where pharmacist Eduard Fresenius established a pharmaceutical manufacturing business in 1912. Over more than a century, the company developed from a producer of infusion solutions and pharmaceutical specialties into a diversified healthcare enterprise serving critically and chronically ill patients. The group’s present operating model is centered on two fully consolidated operating companies: Fresenius Kabi and Fresenius Helios. Fresenius Kabi supplies products used in hospitals and other care settings, including intravenous generic drugs, infusion fluids, clinical and medical nutrition, biopharmaceuticals, and medical devices. Its portfolio is directed toward therapies for patients with serious or chronic conditions and includes products used in oncology, anesthesia, intensive care, parenteral nutrition, and infusion therapy. Fresenius Helios operates private hospitals and outpatient healthcare facilities in Germany and Spain. Its German activities include Helios Kliniken, while its Spanish business includes Quirónsalud. Together, these businesses provide inpatient treatment, outpatient services, diagnostics, occupational health, prevention, and other forms of care along the healthcare continuum. Fresenius also remains a major shareholder in Fresenius Medical Care, the separately listed dialysis company created through the combination of Fresenius’s dialysis business and National Medical Care in 1996. Fresenius Medical Care was deconsolidated from the group in 2023 after changing its legal form and is now treated as an equity-accounted investment. In March 2025, Fresenius announced plans to reduce its holding to 25 percent plus one share, reflecting a strategy of greater portfolio focus and financial flexibility while retaining a significant long-term position. The company previously had a fourth major business area, Fresenius Vamed, which developed, managed, and operated healthcare facilities and provided technical services for medical institutions. Fresenius began a structured exit from Vamed in 2024. The rehabilitation business was divested, Austrian activities were sold to an Austrian consortium, and selected hospital-services activities were transferred into the Fresenius organization. Remaining Vamed activities have been renamed or reorganized, including the creation of Fresenius Health Services for certain technical and infrastructure services. Fresenius’s strategic identity under its recent #FutureFresenius program is that of a focused, therapy-oriented healthcare company rather than a broadly diversified conglomerate. The group emphasizes system-critical products, medical technology, pharmaceutical therapies, hospital care, and operational efficiency. Its competitive position rests on a combination of manufacturing scale, hospital networks, clinical expertise, international distribution, regulated-market capabilities, and long-term relationships with healthcare providers. The business operates in more than 60 countries and has major markets in Europe and North America, with additional activities across Latin America, Asia-Pacific, Africa, and the Middle East. In fiscal year 2025, the principal operating companies were Fresenius Kabi and Fresenius Helios, while Fresenius Medical Care remained a strategic investment. The group reported 2025 revenue of approximately €22.9 billion, excluding discontinued Vamed operations from segment reporting. Fresenius remains publicly listed in Germany and is associated with the nonprofit Else Kröner-Fresenius Foundation, which is the group’s largest shareholder and supports medical research and humanitarian projects.
History
Fresenius traces its commercial origins to the Hirsch Pharmacy in Frankfurt, a pharmacy whose history extends back several centuries and which came into the Fresenius family during the nineteenth century. Eduard Fresenius, a pharmacist who had taken responsibility for the pharmacy’s management, expanded its laboratory into a separate chemical-pharmaceutical manufacturing business. He registered Dr. Eduard Fresenius chemisch-pharmazeutische Industrie in 1912. The early portfolio included injection solutions, serological reagents, pharmaceutical specialties, and other preparations produced on a small scale. In the 1930s, the manufacturing operation was separated from the pharmacy and moved to Bad Homburg near Frankfurt. Eduard Fresenius developed the business through pharmaceutical production, physician relationships, and distribution initiatives. The company was severely affected by the Second World War and its aftermath. When Eduard Fresenius died unexpectedly in 1946, the business was small and financially weakened. His foster daughter, Else Fernau, later known as Else Kröner, assumed responsibility after completing her pharmacy studies. Working with her husband Hans Kröner, she reorganized the company, reduced its debt burden, and built a more industrial and internationally oriented enterprise. During the postwar period, Fresenius expanded its infusion-solutions business. A major strategic turning point came in 1966, when the company began selling dialysis machines and dialyzers manufactured by foreign suppliers. Fresenius subsequently developed its own dialysis technology, including the A2008 dialysis machine introduced in 1979. Dialysis became a foundational growth area and helped establish the group as a major supplier of renal-care products and services. The company also expanded its manufacturing capabilities. In the early 1980s it became involved in the production of polysulfone fiber membranes, an important material used in dialyzers. The corporate structure changed as the business grew: Fresenius was converted into a joint-stock company in the early 1980s and became publicly listed on the Frankfurt Stock Exchange in 1986. These changes provided access to capital for international expansion and acquisitions. In 1996, Fresenius combined its dialysis operations with National Medical Care to create Fresenius Medical Care. The transaction established a separately listed dialysis company that combined equipment, supplies, and clinical services. Fresenius remained a major shareholder and continued to benefit from the expansion of the dialysis platform, while Fresenius Medical Care developed into one of the world’s largest dialysis providers. The late 1990s and 2000s brought further diversification. In 1999, Fresenius combined its pharmaceutical business with Pharmacia & Upjohn’s international nutrition activities to form Fresenius Kabi. Kabi became the group’s platform for infusion therapy, clinical nutrition, generic injectable drugs, and medical devices. Fresenius also entered hospital operations through the acquisition of Wittgensteiner Kliniken in 2001 and the acquisition of Helios in 2005. Helios became the group’s hospital-services platform and expanded across Germany through acquisitions and the development of integrated inpatient and outpatient networks. Fresenius continued to expand Kabi through acquisitions such as Labesfal in Portugal, a majority stake in Dabur Pharma in India, APP Pharmaceuticals in the United States, and later businesses connected with biosimilars, oncology, and medical technology. Helios broadened its German footprint through acquisitions including Humaine Kliniken and Damp Group. In 2013, Fresenius acquired 41 hospitals from Rhön-Klinikum, substantially strengthening Helios’s position in the German private hospital market. In 2017, it acquired the Spanish hospital group Grupo Hospitalario Quirónsalud and integrated it into Helios, creating a major cross-border hospital platform in Germany and Spain. Fresenius also changed its legal form several times as it became more international. In 2007 the company completed its conversion from an Aktiengesellschaft into a Societas Europaea. In 2011 it adopted its current legal form, Fresenius SE & Co. KGaA, with Fresenius Management SE serving as general partner. This structure separates operational management by the general partner from the limited-partner share structure of the listed company. In 2019, Fresenius Medical Care acquired NxStage Medical, strengthening its home-dialysis and portable-dialysis capabilities. Fresenius also participated in the creation of InterWell Health in 2022 through the combination of InterWell Health and Cricket Health, reflecting a broader industry move toward earlier-stage kidney-disease management and value-based care. Under CEO Michael Sen, Fresenius launched the #FutureFresenius transformation and began simplifying its portfolio. Fresenius Medical Care changed its legal form in 2023 and was deconsolidated from the group. In 2024, Fresenius started a structured exit from Vamed, its former facility-management and healthcare-engineering investment company. The rehabilitation business was sold, Austrian activities were transferred to Porr and Strabag, selected hospital-services capabilities were retained, and the remaining activities were reorganized. In 2025, the group continued to emphasize Fresenius Kabi and Fresenius Helios as its operating companies while managing Fresenius Medical Care as a strategic investment. In 2026, Christian Pawlu joined the Management Board with responsibility for Helios, while Michael Sen’s CEO mandate was extended to 2031.
- 2026
Christian Pawlu takes responsibility for Fresenius Helios
[10]Christian Pawlu joins the Management Board on July 1, 2026, succeeding Robert Möller in the board role for Helios.
- 2025
Fresenius proposes reducing its Fresenius Medical Care stake
[6]Fresenius announces a plan to reduce its Fresenius Medical Care holding to 25 percent plus one share as part of its portfolio and capital-allocation strategy.
- 2024
Structured exit from Vamed begins
[7]Fresenius starts withdrawing from Vamed, selling rehabilitation and Austrian activities while transferring selected hospital-services capabilities into the group.
- 2023
Fresenius Medical Care is deconsolidated
[3]Following Fresenius Medical Care’s legal-form conversion, Fresenius treats it as an equity-accounted investment rather than a consolidated subsidiary.
- 2019
NxStage is acquired by Fresenius Medical Care
[12]The acquisition strengthens Fresenius Medical Care’s home-dialysis and portable-dialysis capabilities.
- 2017
Quirónsalud joins Helios
[12]Fresenius acquires Grupo Hospitalario Quirónsalud and integrates it into Helios, creating a major hospital group operating in Germany and Spain.
- 2013
Helios acquires 41 hospitals from Rhön-Klinikum
[12]The transaction substantially expands Helios’s German hospital network.
- 2011
Current KGaA legal form adopted
[12]Fresenius becomes Fresenius SE & Co. KGaA, with Fresenius Management SE as general partner.
- 2007
Conversion to Societas Europaea
[12]Fresenius completes its conversion from an Aktiengesellschaft to a Societas Europaea.
- 2005
Helios is acquired
[2]Fresenius acquires the Helios hospital group and establishes a major hospital-services platform in Germany.
Products and positioning
A therapy-focused global healthcare group supplying essential hospital products while operating large private hospital networks and maintaining a strategic investment in dialysis.
Pharmaceuticals
Fresenius Kabi intravenous drugs and fluids
Fresenius Kabi supplies intravenous generic medicines, infusion solutions, electrolyte products, and other hospital medicines. The portfolio includes products used in anesthesia, intensive care, oncology, anti-infective treatment, and emergency medicine. These products are generally administered in hospitals or other supervised clinical settings and form one of the group’s core manufacturing and distribution platforms.
Clinical nutrition
Clinical and medical nutrition
Fresenius Kabi develops enteral and parenteral nutrition products for patients who cannot obtain sufficient nutrition through ordinary food intake. Its offering includes nutritional formulas, amino-acid solutions, lipid emulsions, and related administration systems used in hospitals, home care, and other clinical environments.
Medical devices
Fresenius Kabi medical technology
The medical-technology portfolio includes infusion pumps, administration systems, devices for clinical nutrition, and other equipment supporting the delivery of medicines and nutrients. These products are designed to integrate with hospital workflows and to support reliable administration for critically and chronically ill patients.
Biopharmaceuticals
Fresenius Kabi biopharmaceuticals
Fresenius Kabi’s biopharmaceutical activities focus on complex biologic and biosimilar medicines used in areas such as immunology, oncology, and other specialty therapies. The platform forms one of the principal growth vectors in the company’s current Kabi strategy.
Hospitals · 2005
Helios Kliniken
Helios Kliniken is Fresenius’s German hospital network. It provides inpatient and outpatient treatment across a broad range of specialties and operates hospitals, medical-care centers, occupational-health facilities, and prevention centers. The network is one of the largest private healthcare systems in Germany.
Hospitals and outpatient care · 2017
Quirónsalud
Quirónsalud is the Spanish hospital and outpatient-care platform integrated into Fresenius Helios after the 2017 acquisition of Grupo Hospitalario Quirónsalud. It provides hospital treatment, diagnostics, outpatient medicine, occupational health, and related healthcare services in Spain and selected Latin American markets.
Dialysis products and services · 1996
Fresenius Medical Care dialysis portfolio
Fresenius Medical Care supplies dialysis machines, dialyzers, concentrates, and related consumables, while also operating dialysis clinics and providing renal-care services. Although separately listed and no longer consolidated by Fresenius, it remains a major strategic investment associated with the Fresenius brand.
Controversies
2021
U.S. criminal resolution over Kalyani records
Fresenius Kabi Oncology Limited agreed to pay $50 million in fines and forfeiture after pleading guilty to concealing and destroying records relevant to an FDA inspection.
2019
Foreign bribery settlement involving Fresenius Medical Care
Fresenius Medical Care agreed to pay approximately $231 million to resolve U.S. Department of Justice and SEC allegations involving bribery and improper payments used to obtain business in Angola, Saudi Arabia, Morocco, and Spain.
2015
Faulty insulin syringes and patient death
Fresenius Kabi and Calea UK were fined in the United Kingdom after syringes supplied to a hospital contained saline rather than insulin. A coroner found the resulting diabetic ketoacidosis to be a major contributory factor in Neil Judge’s death.
2013
Kalyani manufacturing and quality-control investigation
Fresenius Kabi Oncology’s Kalyani, India, facility faced regulatory scrutiny after employees concealed or destroyed records before an FDA inspection. The matter ultimately resulted in a U.S. criminal resolution and compliance obligations.
2012
Hydroxyethyl starch legal-threat controversy
Fresenius Kabi was criticized after reportedly threatening legal action against researcher Anders Perner following publication of research raising safety concerns about hydroxyethyl starch in severe sepsis. European regulators subsequently required suspension measures for HES products.
Marketing campaigns
- 2022#FutureFresenius
Global
The #FutureFresenius transformation program presents Fresenius as a more focused, therapy-oriented healthcare company and emphasizes profitable growth, portfolio simplification, stronger operating companies, and improved capital efficiency.
Outcome. The program was associated with the deconsolidation of Fresenius Medical Care, the exit from Vamed, and a sharper focus on Fresenius Kabi and Fresenius Helios.
- 2012100 Years of Fresenius
Germany · International
Fresenius marked its centenary with historical communications describing its development from the Hirsch Pharmacy laboratory into an international healthcare group.
Outcome. The campaign reinforced the company’s heritage, founder narrative, and association with medical innovation and patient care.
Brand decisions
2025
Reduce Fresenius Medical Care stakeStrategyBackground
Fresenius sought additional financial flexibility and a simpler portfolio while retaining a meaningful position in dialysis.
Action taken
The company announced a combined offering intended to reduce its Fresenius Medical Care stake to 25 percent plus one share.
Aftermath
The transaction was presented as a capital-allocation and balance-sheet measure consistent with the FutureFresenius strategy.
2024
Exit Vamed and simplify the portfolioStrategyBackground
Fresenius identified Vamed as outside the strategic core of its therapy-focused healthcare model.
Action taken
The company initiated a structured exit, sold rehabilitation operations, agreed to sell Austrian activities to Porr and Strabag, transferred hospital-services capabilities into Fresenius, and began scaling back international project activities.
Aftermath
Vamed ceased to be a reporting segment from the second quarter of 2024, while selected technical services continued within the Fresenius organization.
Purchase price for Vamed Austrian activities. €90 million (Announced May 8, 2024)
2023
Deconsolidate Fresenius Medical CareStrategyBackground
Fresenius pursued a more focused operating model and changed its relationship with its separately listed dialysis affiliate.
Action taken
Following Fresenius Medical Care’s conversion into a stock corporation, Fresenius stopped consolidating the company and began accounting for its stake under the equity method.
Aftermath
Fresenius Medical Care became a strategic investment rather than a consolidated reporting segment, simplifying the group’s structure.
2017
Acquire Grupo Hospitalario QuirónsaludM&ABackground
Fresenius aimed to build a larger European private hospital platform with a strong position in Spain.
Action taken
Fresenius acquired Grupo Hospitalario Quirónsalud and integrated it into Helios.
Aftermath
The transaction created a major hospital group operating across Germany and Spain and broadened Fresenius’s inpatient and outpatient care footprint.
Acquisition purchase price. €5.76 billion (2017 acquisition)
2005
Acquire HeliosM&ABackground
Fresenius sought to add direct healthcare delivery and hospital management to its product businesses.
Action taken
Fresenius acquired the Helios hospital group in Germany.
Aftermath
Helios became the foundation of Fresenius’s hospital and outpatient-care operations and later expanded into Spain through Quirónsalud.
1999
Create Fresenius Kabi through pharmaceutical and nutrition integrationM&ABackground
Fresenius wanted to combine its pharmaceutical capabilities with an international nutrition platform.
Action taken
The company merged its international nutrition business acquired from Pharmacia & Upjohn with Fresenius Pharma to form Fresenius Kabi.
Aftermath
Fresenius Kabi became the group’s principal platform for infusion therapy, clinical nutrition, generic injectable drugs, and medical technology.
1996
Combine dialysis operations with National Medical CareM&ABackground
Fresenius sought to scale its dialysis equipment, supplies, and services business internationally.
Action taken
The dialysis business was combined with National Medical Care to form Fresenius Medical Care.
Aftermath
The transaction created a major dedicated renal-care company that later became separately listed and remained a strategic investment of Fresenius.
Recent events
- Unconfirmed
Reported
Fresenius hires new investment manager[17]
German healthcare company Fresenius has hired a new investment manager, as reported by Global Venturing. The report does not name the individual or specify the date of the hire.
Reported
Fresenius launches €200m Fresenius Ventures fund[18]
Fresenius established a dedicated corporate venture capital fund, Fresenius Ventures, with more than €200 million ($231 million) committed over the next five years to invest in biopharma, medtech and care provision areas.
Fresenius filed patent review petitions challenging rheumatoid arthritis patents[19]
Fresenius Kabi USA and Fresenius Kabi SwissBioSim filed Inter Partes Review petitions challenging two patents assigned to Chugai, Roche, and Genentech, asserting that the relevant claims were invalid as anticipated or obvious. These are allegations in the petitions, not a reported decision on their merits.
Reported
Fresenius announces telehealth feature for home dialysis platform[20]
Fresenius announced that a telehealth component was set to be added to its connected health platform for home dialysis. The rollout was planned to begin in select markets, with expansion planned later in 2020.
Sources20 sources
- 1Fresenius official historyfresenius.com
- 2Fresenius: From a local pharmacy to a global corporationfresenius.com
- 3Fresenius Annual Report 2025: The Group’s business modelreport.fresenius.com
- 4Fresenius Annual Report 2025fresenius.com
- 5Fresenius Management Boardfresenius.com
- 6Fresenius announces reduction of Fresenius Medical Care stakefresenius.com
- 7Fresenius exits its Investment Company Vamedfresenius.com
- 8Fresenius Medical Care FCPA settlementjustice.gov
- 9U.S. FDA and DOJ resolution concerning Fresenius Kabi Oncology’s Kalyani facilityfda.gov
- 10Fresenius Medical Care and Christian Pawlu leadership announcementfresenius.com
- 11Fresenius company article on 100 years of historyfresenius.com
- 12Wikipedia: Freseniusen.wikipedia.org
- 13Conversion into a joint-stock companyfresenius.com
- 14Fresenius Kabi is formedfresenius.com
- 15Hydroxyethyl starch legal-threat controversyeur-lex.europa.eu
- 16Faulty insulin syringes and patient deathcapitalfm.com
- 17费森尤斯聘请新投资经理news.google.com
- 18费森尤斯推出2亿欧元Fresenius Ventures基金bioxconomy.com
- 19Fresenius 提交审查申请，挑战类风湿关节炎相关专利jdsupra.com
- 20Fresenius宣布为居家透析平台增加远程医疗功能healio.com
Cite this profile: Cite the canonical profile. /brand-wiki/fresenius · Editorial policy · How profiles are compiled